化合物 T26669 | 222732-94-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 化合物 T26669
• 中文别名: 化合物 T26669
• 英文名称: Asoprisnil ecamate
• 英文别名: [(E)-[4-[(8S,11R,13S,14S,17S)-17-methoxy-17-(methoxymethyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-11-yl]phenyl]methylideneamino] N-ethylcarbamate
• CAS: 222732-94-7
• 化学式: C₃₁H₄₀N₂O₅
• 分子量: 520.7
• InChiKey: XMCOWVOJIVSMEO-RCCUTSCYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  38
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  86.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  [(E)-[4-[(8S,11R,13S,14S,17S)-17-methoxy-17-(methoxymethyl)-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-11-yl]phenyl]methylideneamino] carbonochloridate 生成 化合物 T26669
  参考文献：
  名称：

  11-benzaldoxime-estra-diene derivatives, methods for their production

  摘要：

  本发明涉及新的11-苯甲醛肟-雌二烯衍生物，其通式为I ##STR1## 以及其药学上可接受的盐，其制备方法和含有这种化合物的药物。所述化合物表现出强烈的抗孕激素效应和降低的糖皮质激素活性。

  公开号：

  US05693628A1

文献信息

• Method for the production of 4-(17$g(a)-alkoxymethyl-17$g(b)-substituted 3-oxoestra-4,9-dien-11$g(b)-yl) benzaldehyde-(1e)-oxime derivatives 9-dien-11byl)benzaldehyde-(1-e)-oxime derivatives
  申请人：——

  公开号：US20040059141A1

  公开（公告）日：2004-03-25

  This invention relates to a process for the production of 4-(17&agr;-alkoxymethyl-17&bgr;-substituted-3-oxoestra-4,9-dien-11&bgr;-yl)benzaldehyde-(1E)-oxime derivatives of general formula (I) 1 in which R means an amino group, an O—C 1-7 -alkyl- or O-aryl radical, an S—C 1-7 -alkyl- or S-aryl radical, an NH—C 1-7 -alkyl- or NH-aryl radical or an N-di-C 1-7 -alkyl radical, and R 1 means a hydrogen atom or a C 1-6 -alkyl radical, which yields the target compounds of formula (I) with high yield and selectivity.

  本发明涉及一种生产4-(17&agr;-烷氧甲基-17&bgr;-取代-3-氧代雌-4,9-二烯-11&bgr;-基)苯甲醛-(1E)-肟衍生物的方法，其通式为(I)1，其中R表示氨基、O—C1-7-烷基或O-芳基基团、S—C1-7-烷基或S-芳基基团、NH—C1-7-烷基或NH-芳基基团或N-二C1-7-烷基基团，R1表示氢原子或C1-6-烷基基团，该方法能以高收率和选择性产生目标化合物(I)的方法。
• Process for production of crystals of a medicinally effective ingredient, crystals obtained thereby and pharmaceutical preparations containing them
  申请人：——

  公开号：US20030215516A1

  公开（公告）日：2003-11-20

  The process for making crystals of a medicinally effective ingredient having a predetermined average particle size in a predetermined size range and a maximum particle size that does not exceed a predetermined maximum value, includes subjecting a supersaturated solution containing the medicinally effective ingredient to a wet milling by a wet milling apparatus while crystallizing, in order to obtain a primary particle suspension. Crystals obtained according to this process and pharmaceutical preparations containing them are also described.

  制造药用有效成分晶体的工艺具有在预定粒度范围内的预定平均粒度和不超过预定最大值的最大粒度，包括将含有药用有效成分的过饱和溶液在结晶的同时用湿法研磨设备进行湿法研磨，以获得初级颗粒悬浮液。此外，还介绍了根据该工艺获得的晶体和含有这些晶体的药物制剂。
• Process for production of crystals of 11ss-benzaldoxim-estra-4,9-diene derivatives, crystals obtained thereby and pharmaceutical preparations containing them
  申请人：——

  公开号：US20030225050A1

  公开（公告）日：2003-12-04

  The process for making crystals of a 11&bgr;-benzaldoxim-estra-4,9-diene derivative having a predetermined average particle size in a predetermined size range and a maximum particle size that does not exceed a predetermined maximum value, includes subjecting a supersaturated solution containing a special 11&bgr;-benzaldoxim-estra-4,9-diene derivative of formula (I) to a wet milling by a wet milling apparatus while crystallizing, in order to obtain a primary particle suspension. Crystals obtained according to this process and pharmaceutical preparations containing them are also described.

  11&bgr;-benzaldoxim-estra-4,9-diene 衍生物的晶体具有在预定粒度范围内的预定平均粒度和不超过预定最大值的最大粒度，其制造工艺包括将含有式（I）的特殊 11&bgr;-benzaldoxim-estra-4,9-diene 衍生物的过饱和溶液在结晶的同时用湿法研磨装置进行湿法研磨，以获得初级颗粒悬浮液。此外，还介绍了根据该工艺获得的晶体和含有这些晶体的药物制剂。
• Sequential SPRM/progestin treatment
  申请人：Chwalisz Kristof

  公开号：US20050215535A1

  公开（公告）日：2005-09-29

  The methods provided herein comprise administering a selective progesterone receptor modulator (SPRM) during a first dosing period and at least one progestogen during a second dosing period. The dosing periods can run concomitantly or sequentially with or without a period where neither the SPRM nor the progestogen is administered.

  本文提供的方法包括在第一给药期使用选择性孕酮受体调节剂（SPRM），在第二给药期使用至少一种孕激素。这两个给药期可以同时进行，也可以依次进行，可以有一个既不给药 SPRM 也不给药孕激素的给药期，也可以没有这个给药期。
• Sequential SPRM/ progestin treatment
  申请人：Chwalisz Kristof

  公开号：US20050215536A1

  公开（公告）日：2005-09-29

  The methods provided herein comprise administering a selective progesterone receptor modulator (SPRM) during a first dosing period and at least one progestogen during a second dosing period. The dosing periods can run concomitantly or sequentially with or without a period where neither the SPRM nor the progestogen is administered.

  本文提供的方法包括在第一给药期使用选择性孕酮受体调节剂（SPRM），在第二给药期使用至少一种孕激素。这两个给药期可以同时进行，也可以依次进行，可以有一个既不给药 SPRM 也不给药孕激素的给药期，也可以没有这个给药期。